THI Continues to Play a Pivotal Role in the Latest Development in the Field of Artificial Heart Technology
The Texas Heart Institute partner, BiVACOR, gets additional support Total Artificial Heart program
With plans for an FDA-granted investigational device exemption (IDE) first-in-human Early Feasibility Study in 2024, The Texas Heart Institute, known for its groundbreaking research and innovation in cardiovascular care, is working closely with renowned cardiovascular surgeons Dr. O.H. (Bud) Frazier and Dr. William E. Cohn, to lead the way in advancing the treatment of severe heart failure.
As a key partner in the Artificial Heart Frontiers Program (AHFP), led by Monash University in Australia, BiVACOR®, has been awarded $13 million from the Australian Government’s Medical Research Future Fund (MRFF) to support the Total Artificial Heart program and future product enhancements.
This funding will not only facilitate the clinical work of the BiVACOR Total Artificial Heart but also spur the development of wireless power sources for the device.
